Total Return chart Agenus Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
6.040 ^USD	-9.58%		-21.25%	+92.36%

10-08	Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination	MT
10-08	Agenus Inc. Receives Marketing Authorizations in Armenia for Botvymo and Evamplix for Use in Combination in Previously Treated Mss Metastatic Colorectal Cancer	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.